Prothena Corp

PRTA

Market cap $501M

9.31 USD

-0.17

1.79%

At close Updated Dec 30, 4:00 PM EST

Pre-market

After hours

9.28

-0.03

0.32%

1 day

-1.79%

5 days

-2.31%

1 month

-9.35%

3 months

-4.61%

6 months

53.38%

Year to date

-31.89%

1 year

-37.43%

5 years

-24.8%

10 years

-86.66%

About: Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

Employees: 163

Healthcare Biotechnology